Oct 18, 2023
Allergies are on the rise globally, affecting millions of people and significantly impacting their quality of life. The ability to accurately diagnose and manage allergies is crucial for both patients and healthcare providers. With the rising prevalence of allergy, the demand for Allergy Diagnostics has increased m...
Read More...
Oct 16, 2023
Rare eye diseases can pose burden on patients. Top rare eye diseases are Stargardt Disease, Retinitis Pigmentosa, LHON, Retinoblastoma, LSCD
Read More...
Oct 13, 2023
On September 29, 2023, FDA approved EXXUA, the ER gepirone hydrochloride tablets by Fabre-Kramer, for major depressive disorder treatment.
Read More...
Oct 11, 2023
Immunomodulators are reshaping the healthcare market outlook with their diverse benefits and applications, thereby improving health outcomes.
Read More...
Oct 09, 2023
FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.
Read More...
Oct 06, 2023
Since scopolamine transdermal patch FDA approval, no other treatments approved in US for nausea and vomiting induced by motion sickness.
Read More...
Oct 04, 2023
Alzheimer’s Disease represents one of the most pressing challenges in today's healthcare market. As its prevalence continues to soar with the aging global population, the hurdles in its diagnostic and treatment also continue to rise. As per the estimate, globally, about 55 million people are living with dementia in...
Read More...
Sep 29, 2023
With rise of gene therapy and other innovative therapeutic approaches, we experience profound change in Netherton syndrome treatment space.
Read More...
Sep 27, 2023
It is not surprising that the healthcare sector is undergoing a significant transition in an era characterized by technological developments and the digitization of almost every aspect of our lives. The development of smart medical devices is a shining illustration of how technology has advanced in healthcare in a ...
Read More...
Sep 22, 2023
FDA approved GSK's momelotinib, marketed under name Ojjaara, for management of myelofibrosis in adult patients suffering from anemia.
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper